SomaLogic completed the acquisition of Palamedrix for $53m.

SomaLogic, a developer of AI data-driven proteomics technology, completed the acquisition of Palamedrix, an innovator in DNA nanotechnology, for $53m. “We are excited to announce our strategic acquisition of Palamedrix, accelerating our vision to make the SomaScan Platform more accessible to a broader group of customers, and to meet their diverse needs. This acquisition enhances our future opportunity for growth while allowing SomaLogic to maintain its strong balance sheet. It also expands our footprint to San Diego, California, one of the nation’s leading biotechnology centers of excellence as we continue our work to leverage the power of proteomics to positively impact human health," Roy Smythe, SomaLogic CEO.